A 52-year-old woman with newly diagnosed multiple myeloma presents to the oncology clinic. She has been started on a combination chemotherapy regimen including an alkylating agent. After 3 months of therapy, she develops severe bone marrow suppression with a hemoglobin of 7.2 g/dL, WBC 2100/μL, and platelets 45,000/μL. Additionally, she reports dysuria and hematuria. Urinalysis shows RBCs and WBCs in the urine. Which alkylating agent is most likely responsible for this constellation of findings, and what is the primary mechanism of its urinary toxicity?

Question

Accepted Answer

B. Cyclophosphamide; acrolein metabolite causes direct mucosal irritation. ## Cyclophosphamide and Urinary Toxicity

**Key Point:** Cyclophosphamide is metabolized to acrolein, a highly reactive aldehyde that is excreted in the urine and causes direct chemical irritation of the bladder mucosa, leading to hemorrhagic cystitis.

### Mechanism of Acrolein-Induced Cystitis

1. **Hepatic activation**: Cyclophosphamide undergoes hepatic oxidation via cytochrome P450 to form phosphoramide mustard (active alkylating form) and acrolein (toxic metabolite).
2. **Urinary excretion**: Acrolein is water-soluble and concentrated in the urine, where it accumulates in the bladder.
3. **Mucosal damage**: Acrolein causes direct chemical irritation, inflammation, and ulceration of the bladder epithelium.
4. **Clinical manifestation**: Results in hemorrhagic cystitis with dysuria, hematuria, and increased urinary frequency.

### Prevention and Management

| Strategy | Mechanism | Efficacy |
| --- | --- | --- |
| Aggressive hydration | Dilutes urine acrolein concentration | Highly effective |
| Frequent voiding | Reduces bladder dwell time | Highly effective |
| Mesna (2-mercaptoethanesulfonate) | Inactivates acrolein by conjugation | Gold standard |
| Bladder irrigation | Mechanical removal of irritants | Supportive |

**High-Yield:** Mesna is a uroprotective agent that must be given with cyclophosphamide (dose = 20–40% of cyclophosphamide dose, given at 0, 4, and 8 hours). It is the standard of care for high-dose cyclophosphamide regimens.

**Clinical Pearl:** Hemorrhagic cystitis can occur acutely (during or shortly after infusion) or late (months to years after therapy), and severe cases may lead to bladder fibrosis and reduced capacity.

### Why Cyclophosphamide Over Other Alkylating Agents

Cyclophosphamide is unique among alkylating agents in its production of acrolein. Melphalan, chlorambucil, and busulfan do not generate this specific toxic metabolite and are not associated with hemorrhagic cystitis.

**Mnemonic: ACROLEIN = Alkylating agent Cyclophosphamide Reactive Oxidative Lesion Excreted IN urine**

Answer

A. Melphalan; inactive metabolites accumulate in bladder epithelium

Answer

C. Chlorambucil; forms stable DNA adducts in urothelium

Answer

D. Busulfan; undergoes hepatic metabolism producing toxic sulfur compounds

Explanation

Practice similar questions